Erythrocytosis and Polycythemia Vera

Erythrocyte Physiology and Hemoglobin Metabolism

Under normal conditions, an erythrocyte is an anucleated biconcave disc measuring 7–8 µm in diameter (normocyte). This shape is physiologically advantageous: it provides the maximum surface-area-to-volume ratio, ensuring highly efficient gas exchange with tissues. The lifespan of a circulating erythrocyte is 100–120 days.

Physiological hemolysis (destruction of senescent erythrocytes) occurs primarily in the spleen, as well as in the liver and bone marrow. The breakdown of hemoglobin involves the following stages:

1. Cleavage of hemoglobin into heme and globin.
2. Globin metabolism: The protein moiety is degraded into amino acids.
3. Heme metabolism: Heme is broken down into iron and protoporphyrin.
4. Iron pathway: Binds to the transport protein transferrin and is carried to the bone marrow, liver, and muscles for reutilization.
5. Protoporphyrin pathway: Converted into carbon monoxide (CO) and biliverdin. Biliverdin is then reduced to free ( unconjugated) bilirubin.
6. Transport and conjugation: Unconjugated bilirubin binds to albumin and is transported via the bloodstream to the liver. There, it is conjugated with glucuronic acid to form direct (conjugated) bilirubin.
7. Excretion: As a component of bile, conjugated bilirubin enters the intestine, where it is transformed into urobilinogens.
8. Elimination: The majority is excreted in feces, while a smaller fraction is reabsorbed into the bloodstream and excreted by the kidneys in urine.

Classification of Erythrocytosis

Based on their etiology, all forms of erythrocytosis are divided into two major groups:

• Primary erythrocytoses: Polycythemia vera and familial (inherited) forms.
• Secondary erythrocytoses:
• Absolute (true increase in red blood cell mass).
• Relative (hemoconcentration and redistribution).

Etiology and Pathogenesis of Polycythemia Vera

The primary cause of polycythemia vera involves carcinogenic agents, with a major risk factor being decreased efficacy of the body's antitumor defense mechanisms.

Key Pathogenetic Mechanisms:

1. Exposure to a carcinogen induces a neoplastic transformation in the genome of a multipotent hematopoietic progenitor cell.
2. The pool of proliferating neoplastic progenitor cells undergoing myeloid lineage commitment increases sharply in the hematopoietic tissue.
3. Genetic mutations affect genes whose products are responsible for signal transduction from hematopoietic growth factor receptors.
4. Due to this mutation, hematopoietic cells acquire hypersensitivity to hematopoietic growth factors.
5. As a result, the division rate of the myeloid lineage cells multiplies significantly, even though the level of stimulatory factors (specifically erythropoietin) remains within the normal range.

Note: Aside from neoplastic Vaquez's disease, there are familial inherited non-myeloproliferative disorders. These are caused by non-neoplastic transformation of the erythroid lineage, yet they are also accompanied by an increased red blood cell count, hypervolemia, and features mimicking true polycythemia.

Hematological Manifestations (Vaquez's Disease)

In polycythemia vera, the primary pathological changes are localized in the bone marrow and peripheral blood.

Bone Marrow Changes: Panmyelosis is observed—total neoplastic proliferation of myeloid cells along with accelerated iron turnover. In the terminal stages of the disease, bone marrow exhaustion occurs, leading to post-polycythemic myeloid metaplasia with myelofibrosis, which results in pancytopenia (a decrease in all blood cell lineages).

Peripheral Blood Changes: A polycythemia symptom complex develops (panmyelosis in peripheral blood — expansion of all hematopoietic lineages):

• Erythroid lineage: Marked erythrocytosis, reticulocytosis (due to the release of immature neoplastic cells), erythrocyte hypochromia, elevated hematocrit, and hemoglobin levels above normal limits.
• Thrombocytic lineage: Thrombocytosis.
• Leukocytic lineage: Leukocytosis.

Physicochemical Shifts and Systemic Consequences: Cellular excess leads to hypervolemia (plethora) and a sharp rise in blood viscosity. This triggers severe systemic consequences: cardiovascular dysfunction, impairment of other organ systems, and the development of life-threatening thrombohemorrhagic complications.